MyFinsight
Home
Blog
About
Proceeds from exercise of
stock options
$26K
Effect of exchange rate
changes on cash and cash...
$262K
(-53.87%↓ Y/Y)
Net cash provided by
financing activities
$26K
(-97.86%↓ Y/Y)
Decrease in cash and cash
equivalents
-$426,340K
(-5715.58%↓ Y/Y)
Canceled cashflow
$288K
Proceeds from marketable
securities
$159,419K
(-52.70%↓ Y/Y)
Stock-based compensation
expense
$16,732K
(-35.37%↓ Y/Y)
Accounts payable and
accrued liabilities
$5,716K
(296.16%↑ Y/Y)
Depreciation of property
plant and equipment
$558K
(-56.78%↓ Y/Y)
Non-cash operating lease
expense
$325K
(-49.92%↓ Y/Y)
Other liabilities
$41K
Net cash provided by
(used in) investing...
-$331,238K
(-383.67%↓ Y/Y)
Net cash used in
operating activities
-$95,390K
(24.22%↑ Y/Y)
Canceled cashflow
$159,419K
Canceled cashflow
$23,372K
Purchases of marketable
securities
$490,382K
(122.85%↑ Y/Y)
Net loss
-$110,736K
(26.05%↑ Y/Y)
Purchases of property,
plant and equipment
$275K
(37.50%↑ Y/Y)
Prepaid expenses and
other current assets
$2,501K
(-61.00%↓ Y/Y)
Interest receivable and
accretion of discounts on...
$2,031K
(131.22%↑ Y/Y)
Deferred income tax
recovery
-$1,944K
(-40.56%↓ Y/Y)
Other receivables
$467K
(222.89%↑ Y/Y)
Unrealized foreign
exchange gain
$458K
(1535.71%↑ Y/Y)
Operating lease liability
-$358K
(42.72%↑ Y/Y)
Realized (gain) loss on
marketable securities
$267K
(151.54%↑ Y/Y)
Back
Back
Cash Flow
logo_icon_teal_2280px-svg
Xenon Pharmaceuticals Inc. (XENE)
logo_icon_teal_2280px-svg
source: myfinsight.com
Xenon Pharmaceuticals Inc. (XENE)